https://ejgo.org The article by Petrillo and colleagues [1] recently presents the cisplatin (CDDP) pharmacokinetic profile in a prospective series of patients enrolled in the HORSE (NCT01539785) trial, a randomized controlled… Click to show full abstract
https://ejgo.org The article by Petrillo and colleagues [1] recently presents the cisplatin (CDDP) pharmacokinetic profile in a prospective series of patients enrolled in the HORSE (NCT01539785) trial, a randomized controlled trial exploring the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) for women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS). In this study, the authors highlight for the first time that MI route enhances CDDP peritoneal tissue uptake during HIPEC procedures.
Journal Title: Journal of Gynecologic Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!